Hypogonadism and prostate cancer detection on multiparametric MRI and mpMRI-TRUS fusion biopsy

ConclusionsHypogonadism is an independent predictor of lower CS cancer detection on systematic biopsy. However, it fails to significantly impact CS detection on fusion biopsy with comparable cancer detection rates in both groups. Patients with hypogonadism may benefit more from fusion biopsy than normogonadal patients.
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research